CN105535043A - Medicine composition for treating ascites due to cirrhosis - Google Patents

Medicine composition for treating ascites due to cirrhosis Download PDF

Info

Publication number
CN105535043A
CN105535043A CN201610047139.0A CN201610047139A CN105535043A CN 105535043 A CN105535043 A CN 105535043A CN 201610047139 A CN201610047139 A CN 201610047139A CN 105535043 A CN105535043 A CN 105535043A
Authority
CN
China
Prior art keywords
weight portion
pharmaceutical composition
ethanol
percent concentration
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610047139.0A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610047139.0A priority Critical patent/CN105535043A/en
Publication of CN105535043A publication Critical patent/CN105535043A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine composition for treating ascites due to cirrhosis and a preparation method thereof. The medicine composition is prepared from Diplazium donahue(Mett.)Tard-Blot., Grewia lantsangensis Hu, Aurantio-obtusin, CGlepidotin C and emodin monomethyl ether diglucoside in a matching mode. Various dosage forms can be prepared according to a normal formulation technology, and the medicine composition has the remarkable effect on treating ascites due to cirrhosis.

Description

The pharmaceutical composition for the treatment of cirrhotic ascites
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof.
Background technology
Ascites causes because of retention of sodium and water, the cause of disease of cirrhotic ascites is relevant with following factors: portal venous pressure increases (more than 300mmH2O), hypoalbuminemia, albumin is lower than 30g/L), liver lymph fluid generates too much (normal 1 ~ 3L, now 7 ~ 11L), and Secondary cases aldosterone and vassopressin increase, the molten quantity not sufficient of Efficient Cycle blood (sympathetic activation strengthens, and prostaglandin, atrial natriuretic peptide and kassinin kinin reduce).A large amount of ascites causes abdominal tympanites, and present frog abdomen, abdomen is sagging.Though western medical treatment cirrhotic ascites has certain curative effect, late result is not good enough, and relapse rate is high, and complication is many, and huge medical expense also makes patient hang back.The traditional Chinese medical science uses Chinese medicine from too many levels, Mutiple Targets on dialectical basis, and treatment cirrhotic ascites, curative effect is certainly, safe, economical, has the unrivaled superiority of doctor trained in Western medicine.But current Chinese medicine is observed mainly using the change of clinical symptoms and sign as the evaluation to therapeutic effect, less to objectivity index study.Therefore on differentiation of tcm basis in conjunction with modern Western medicine theory, carry out the research for the treatment of cirrhotic ascites herbal pharmacology, facing the physical and chemical index of card in conjunction with microcosmic as the standard evaluating clinical efficacy, is the direction of Hepatocirrhosis in Chinese Herbal Medicine ascites research.
Comb leaf: this product is Athyriaceae Diplazium donianum (Mett.) Tard. Blet. platymiscium Diplazium donianum (Mett.) Tard. Blet. Diplaziumdonianum(Mett.) herb of Tard-Blot. ［ AspleniumdonianumMett. ］.The whole year all can gather, and cleans, dries.[nature and flavor] micro-hardship; Cold.[function cures mainly] clearing away heat-damp and promoting diuresis; Removing pathogenic heat from blood and toxic substance from the body.Main jaundice due to damp-heat; Venom; Traumatic hemorrhage; Dysmenorrhea.[chemical analysis] is containing makisterone (makisterone) A, B and D.[former phytomorph] plant height 30-60cm.Rhizome is long and grow wild, sturdy, top and petiole base close by black, lanceolar scale, there is little tooth at edge.Ye Jinsheng; The long 15-30cm of petiole, straw color, hard; Blade ground paper matter, without hair, Long Circle or ovum shape Long Circle, long 20-40cm, wide 15-20cm, a pinniform; The raw accessory pinna 2-5 couple in side, alternate, obliquely, has short handle, oval shape lanceolar or ovum shape lanceolar, long 10-16cm, wide 2.5-5cm, top gradually point slightly in shape of tail, the wealthy wedge shape of base portion, full edge or dredge sawtooth to top tool, the raw accessory pinna similar shape of the raw accessory pinna in top and side; Middle veinclearing shows, and has shallow groove above, and justify below and swell, lateral vein pinniform bifurcated, slightly obliquely, often group has scun 3-5 bar, through limb.Sporangiorus is linear, usually twin in the both sides up and down of scun, and often organizing on lateral vein has 1-2 bar, and near, arteries and veins stretches out, and severally reaches limb; Indusium similar shape, film quality.Record in Chinese medicine voluminous dictionary.
Prairie fire rope: this product is the root white skin of Tiliaceae load bar platymiscium comospore bilobed grewia GrewiaeriocarpaJuss. ［ G.lantsangensisHu ］.Autumn, winter take root, strip root bark, and removing cork, cutting, dries.[nature and flavor] are puckery; Micro-hardship; Cool.[function cures mainly] stops blooding; Synthetism; Granulation promoting; Removing toxic substances.Main traumatic hemorrhage; Weapons damage; Fracture; Furuncle is red and swollen.[original shape state] comospore bilobed grewia shrub or dungarunga, up to 8m.Twig is by the starlike soft fine hair of taupe.Leaf alternate; Time handle long 5-10mm; Stipule wire lanceolar, long 5-10mm; Blade papery, tiltedly avette to ovum shape Long Circle, long 6-13cm, wide 3-6cm, tip is point or anxious point gradually, base portion deflection, tiltedly circular or bevel shape, above scattered stellate hair, blackening brown after dry, below by the starlike soft fine hair of Lycoperdon polymorphum Vitt, there is serration at edge; Trinervious two lateral veins rise and reach 3/4 of leaf length, and the middle arteries and veins first half has lateral vein 3-4 couple.Cyme 1-3 branch axil is raw, long 1.5-3cm, the long 3-8mm of common peduncle; The long 3-5mm of anthocaulus; Bract lanceolar; Flower both sexes; The long and narrow circle of sepal, long 6-8mm, inside and outside two sides is all without hair; The long 3mm of petal; Body of gland is short and small; Androgynophore is by hair; Stamen is from life, different in size, shorter than sepal; Ovary is by hair, and style has pubescence, stigma peltate, and 4 shallowly split or do not divide.Drupe is subsphaeroidal, diameter 6-8mm, by stellate hair, has shallow ridges.Record in Chinese medicine voluminous dictionary.
Scale leaf glycyrrhizin C(GlepidotinC): CAS 87440-56-0, molecular formula C 20h 20o 5, molecular weight 340.38.[pharmacological action] is antibacterial.[ingredient origin] pulse family American licorice Glycyrrhizalepidota.
Physcione diglucoside (PhyscionDiglucoside): CAS 84268-38-2, molecular formula C 28h 32o 15, molecular weight 608.55.[pharmacological action] cathartic.[ingredient origin] Polygonaceae sorrel root; Pulse family wart Semen Cassiae; Rhamnaceae branch Fructus rhamni (Rhamnus davurica Pall.).
Aurantio-obtusin (Aurantio-obtusin): CAS 67979-25-3, molecular formula C 17h 14o 7, molecular weight 330.29.[pharmacological action] suppresses platelet aggregation.[ingredient origin] Semen Cassiae Cassiatora.
3 crude drug chemical constitutions:
Physcione diglucoside (PhyscionDiglucoside)
Scale leaf glycyrrhizin C(GlepidotinC) aurantio-obtusin (Aurantio-obtusin).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment cirrhotic ascites and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment cirrhotic ascites are:
Comb leaf 2000-2030 weight portion prairie fire rope 1090-1100 weight portion aurantio-obtusin 105-107 weight portion scale leaf glycyrrhizin C202-204 weight portion physcione diglucoside 82-84 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of cirrhotic ascites, be made up of the crude drug of following weight portion:
Comb leaf 2015 weight portion prairie fire rope 1095 weight portion aurantio-obtusin 106 weight portion scale leaf glycyrrhizin C203 weight portion physcione diglucoside 83 weight portion.
Treat a pharmaceutical composition for cirrhotic ascites, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for cirrhotic ascites, it is characterized in that the treatment cirrhotic ascites medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: comb leaf 2000-2030 weight portion prairie fire rope 1090-1100 weight portion aurantio-obtusin 105-107 weight portion scale leaf glycyrrhizin C202-204 weight portion physcione diglucoside 82-84 weight portion
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Preferably treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: comb leaf 2015 weight portion prairie fire rope 1095 weight portion aurantio-obtusin 106 weight portion scale leaf glycyrrhizin C203 weight portion physcione diglucoside 83 weight portion;
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat cirrhotic ascites medicine.
Medicine composite for curing cirrhotic ascites is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are: comb leaf 2015g prairie fire rope 1095g aurantio-obtusin 106g scale leaf glycyrrhizin C203g physcione diglucoside 83g;
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 2: pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are: comb leaf 2000g prairie fire rope 1100g aurantio-obtusin 105g scale leaf glycyrrhizin C204g physcione diglucoside 82g;
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 3: pharmaceutical composition for the treatment of cirrhotic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are: comb leaf 2030g prairie fire rope 1090g aurantio-obtusin 107g scale leaf glycyrrhizin C202g physcione diglucoside 84g;
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 208g, adds starch 101g, mixing, granulates, dry, adds microcrystalline Cellulose 29g, magnesium stearate 1g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 152g, adds starch 141g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 319g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 12.4g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 5 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 1.7cm apart from liquid level, drips speed with per minute 50 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of cirrhotic ascites
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are:
Aurantio-obtusin 300 weight portion scale leaf glycyrrhizin C210 weight portion physcione diglucoside 68 weight portion.
Embodiment 8: the pharmaceutical composition for the treatment of cirrhotic ascites
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are:
Aurantio-obtusin 202 weight portion scale leaf glycyrrhizin C190 weight portion physcione diglucoside 93 weight portion.
Embodiment 9: the pharmaceutical composition for the treatment of cirrhotic ascites
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of cirrhotic ascites are:
Aurantio-obtusin 125 weight portion scale leaf glycyrrhizin C130 weight portion physcione diglucoside 60 weight portion.
Experimental example 1: the experimental study for the treatment of cirrhotic ascites
1 clinical data
In 24 examples, man 12 example, female 12 example; The oldest 63 years old, minimum 47 years old, average 54 years old.All be diagnosed as icteric liver cirrhosis hepatic ascites in mid-term through ultrasound diagnosis, detection HBV"liang dui ban", liver function.
Clinical manifestation is that enlarged abdomen heavily fortified point is full, and body icteric sclera contaminates, and face is golden yellow or as sootiness, or breast abdomen red filament continuously, poor appetite, or vomiting and nausea, constipation or loose stool, oliguria and yellow, red tongue with yellowish and greasy fur or light red tongue white and thin fur, wiry and frequent pulse or slow.
2 Therapeutic Method
Combination of oral medication (embodiment 1 pharmaceutical composition lot number 20091014), each 1g, every day 3 times 1 month is a course for the treatment of.
3 criterions of therapeutical effect
Cure: clinical symptoms and sign disappear, B ultrasonic detects liver morphology, size recovery is normal, and ascites disappears, and liver function detects to be recovered normally.Take a turn for the better: clinical symptoms and sign alleviate, B ultrasonic detects liver morphology, size recovery is normal, and ascites reduces, and liver function detects not to be recovered completely.Invalid: clinical symptoms and sign are without alleviating, and B ultrasonic detects liver morphology, size without obvious recovery, and ascites volume is without obvious minimizing, and liver function detects without significant change.
4 therapeutic outcomes
1 course for the treatment of cures 3 examples, and 2 courses for the treatment of cure 7 examples, and 3 courses for the treatment of cure 10 examples, and take a turn for the better 12 examples, invalid 2 examples, total effective rate 91.67%.
5 model cases
Week certain, female, 35 years old, first visit on March 18 in 2010.Enlarged abdomen heavily fortified point is full, and body icteric sclera contaminates, edema of lower limbs, tending to vomit of feeling sick, oliguria and yellow, and constipation, red tongue with yellow fur is slightly greasy, wiry and frequent pulse.It is splenauxe that B ultrasonic detects liver, HBV"liang dui ban" detects HBsAg (+), HBs (-), HBeAg (-), HBe (+), HBc (-), total bilirubin 21.5 μm of ol/L, conjugated bilirubin 9.7 μm of ol/L, unconjugated bilirubin 11.5 μm of ol/L, total protein 51g/L, albumin 32g/L, globulin 20g/L, glutamate pyruvate transaminase 84U/L.Be diagnosed as tympanites.Dialectically to pent up for hydro-thermal.Control with clearing away heat-damp and promoting diuresis, capture and relieve oedema or abdominal distension through diuresis or purgation.Pharmaceutical compositions (embodiment 1 pharmaceutical composition lot number 20091014), each 1g, every day 3 times.After taking 3 days, abdominal distention is large, and edema of lower limbs alleviates, and body icteric sclera dye fades, and there are no vomiting and nausea sense, normal urination, color are yellowish, free movement of the bowels, and red tongue with yellow fur is slightly greasy, wiry and frequent pulse.After taking 7 days, abdominal distention, edema of lower limbs obviously alleviate, and body order is without obvious xanthochromia, and anorexia, defecation is normal, and light red tongue tongue is slightly yellow greasy, and stringy pulse delays.After taking 10 days, abdominal distention, edema of lower limbs disappear substantially, and food of receiving is cumulative, and body icteric sclera dye Periostracum Cicadae, defecation is normal, light red tongue yellow and thin fur, moderate pulse.Check B ultrasonic shows that liver morphology, size recover normal, and ascites disappears, and HBV"liang dui ban" detects unchanged, and liver function detects recovers normal.

Claims (8)

1. treat a pharmaceutical composition for cirrhotic ascites, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Comb leaf 2000-2030 weight portion prairie fire rope 1090-1100 weight portion aurantio-obtusin 105-107 weight portion scale leaf glycyrrhizin C202-204 weight portion physcione diglucoside 82-84 weight portion.
2. a kind of pharmaceutical composition for the treatment of cirrhotic ascites according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Comb leaf 2015 weight portion prairie fire rope 1095 weight portion aurantio-obtusin 106 weight portion scale leaf glycyrrhizin C203 weight portion physcione diglucoside 83 weight portion.
3. a kind of pharmaceutical composition for the treatment of cirrhotic ascites according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of cirrhotic ascites according to claim 1, is characterized in that the treatment cirrhotic ascites medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of cirrhotic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: comb leaf 2000-2030 weight portion prairie fire rope 1090-1100 weight portion aurantio-obtusin 105-107 weight portion scale leaf glycyrrhizin C202-204 weight portion physcione diglucoside 82-84 weight portion;
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
6. a kind of preparation method for the treatment of the pharmaceutical composition of cirrhotic ascites according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: comb leaf 2015 weight portion prairie fire rope 1095 weight portion aurantio-obtusin 106 weight portion scale leaf glycyrrhizin C203 weight portion physcione diglucoside 83 weight portion;
Preparation method:
(1) comb leaf is got by crude drug proportioning, prairie fire rope, aurantio-obtusin, scale leaf glycyrrhizin C, physcione diglucoside, mixing, with weight percent concentration 28% ethanol as solvent, extract at 27 DEG C of warm macerating, extraction time is 11 times, each extraction time is 32 hours, each solvent load is 39 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.14, filter, medicinal liquid is by HPD400 macroporous adsorptive resins, first wash with water, use weight percent concentration 47% alcoholic solution eluting HPD400 macroporous adsorptive resins again, collect weight percent concentration 47% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 53% ethanol as solvent, heating and refluxing extraction 13 times, each extraction time is 0.1 hour, each solvent load is 19 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.08, filter, medicinal liquid is by LKS03 macroporous adsorptive resins, first wash with water, use weight percent concentration 69% alcoholic solution eluting LKS03 macroporous adsorptive resins again, collect weight percent concentration 69% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
7. a kind of preparation method for the treatment of the pharmaceutical composition of cirrhotic ascites according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of cirrhotic ascites according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats cirrhotic ascites medicine.
CN201610047139.0A 2016-01-25 2016-01-25 Medicine composition for treating ascites due to cirrhosis Withdrawn CN105535043A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610047139.0A CN105535043A (en) 2016-01-25 2016-01-25 Medicine composition for treating ascites due to cirrhosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610047139.0A CN105535043A (en) 2016-01-25 2016-01-25 Medicine composition for treating ascites due to cirrhosis

Publications (1)

Publication Number Publication Date
CN105535043A true CN105535043A (en) 2016-05-04

Family

ID=55814968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610047139.0A Withdrawn CN105535043A (en) 2016-01-25 2016-01-25 Medicine composition for treating ascites due to cirrhosis

Country Status (1)

Country Link
CN (1) CN105535043A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727859A (en) * 2016-12-10 2017-05-31 济南昊雨青田医药技术有限公司 It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106727859A (en) * 2016-12-10 2017-05-31 济南昊雨青田医药技术有限公司 It is a kind of to treat pharmaceutical composition of pharyngitis and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102205107B (en) Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof
CN103223111B (en) Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof
CN105535095A (en) Medicine composition for treating liver ascites
CN105535043A (en) Medicine composition for treating ascites due to cirrhosis
CN102038821B (en) Method for preparing medicinal composition for treating dysmenorrhea
CN105287921A (en) Medicinal composition for treating gastric cancer and preparation method thereof
CN106109551A (en) A kind of pharmaceutical composition preventing and treating chloasma
CN106620045A (en) Preparation method and application of 95% ethanol extract of clerodendrum japonicum roots
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN106729101B (en) Traditional Chinese medicine composition for treating post-circulation ischemic stroke and preparation method thereof
CN105560694A (en) Medicine composition for treating diabetic nephropathy and preparation method thereof
CN105535058A (en) Medicine composition for preventing and treating pancreatic cancer
CN104666712A (en) Traditional Chinese medicine composition for treating dysmenorrheal with deficiency of qi and blood and preparation method of traditional Chinese medicine composition
CN105596477A (en) Medicine composition for treating ascites due to cirrhosis
CN106668347A (en) Medical composition for treating thyroid diseases
CN115887545A (en) Traditional Chinese medicine composition, product containing traditional Chinese medicine composition, preparation method and application of traditional Chinese medicine composition
CN103223146B (en) Traditional Chinese medicine composition for nursing or treating irregular menstruation after cesarean section
CN106668288A (en) Pharmaceutical composition for treating recurrent oral ulceration
CN111544512A (en) Heat-clearing anus suppository containing flos Trollii and preparation method thereof
CN110638946A (en) Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura
CN106038648A (en) Pharmaceutical composition for preventing and treating esophagus cancer and preparation method thereof
CN106581095A (en) Medicinal composition for treating neurodermatitis
CN106728625A (en) A kind of pharmaceutical composition for treating rhinitis
CN106511425A (en) Pharmaceutical composition for curing acnes
CN106581094A (en) Pharmaceutical composition for treating acne

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160504